Clinical Trials Logo

Filter by:
NCT ID: NCT03786016 Active, not recruiting - Clinical trials for Stress, Psychological

Evaluating Risk Factors and Biomarkers for Adaptation and Resilience to Spaceflight

Start date: February 22, 2019
Phase: N/A
Study type: Interventional

This study assesses differences in biological and behavioral domains that relate to individual adaptation and resiliency to an isolated, confined and controlled environment, and evaluates the effect of confinement, work, monotony, and social and physical isolation on stress resiliency and well-being.

NCT ID: NCT03785964 Active, not recruiting - Desmoid Tumor Clinical Trials

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

DeFi
Start date: April 17, 2019
Phase: Phase 3
Study type: Interventional

This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. Once participants are eligible to roll into the open-label phase, they will receive nirogacestat.

NCT ID: NCT03785873 Active, not recruiting - Clinical trials for Biliary Tract Cancer

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Start date: May 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin for patients with advanced or metastatic biliary tract cancer after progression on first-line systemic therapy.

NCT ID: NCT03785834 Active, not recruiting - Cellulitis Clinical Trials

The Effect of Histopathologic Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis

Start date: May 25, 2018
Phase:
Study type: Observational

The Investigators wish to study the value of dermatologic testing assessments in differentiating between cellulitis and pseudocellulitis in the inpatient setting. The Investigators propose that by utilizing cutaneous biopsies and tissue cultures in patients that have been admitted to inpatient internal medicine teams, the investigators may be able to improve multiple measures of hospital efficiency in patients presenting with cellulitis-like symptoms, by more accurately recognizing cellulitis from pseudocellulitis. The patient will undergo encrypted digital imaging for his or her condition. This image will then be sent to the study investigators, along with basic clinical information on the skin evaluation form. The study investigators will develop a differential diagnosis and then the patient will undergo a skin biopsy. The patient will then be randomized to one of two arms using a random number generator: A) Skin biopsies and tissue cultures recorded and published in patient's medical chart as they would be in a standard of care procedure B) Skin biopsies and tissue cultures consultation performed but not published in the patient's medical chart unless medically necessary. Information will be collected from medical records in IHIS. Patients will be contacted by phone 30 days after discharge.

NCT ID: NCT03785366 Active, not recruiting - Clinical trials for Women at Risk for Pregnancy

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

IUD
Start date: December 17, 2018
Phase: Phase 3
Study type: Interventional

to Assess the Pharmacokinetic Properties of VeraCeptā„¢ Intrauterine Contraceptive vs ParaGard® in Healthy, Post- Menarcheal Women

NCT ID: NCT03784287 Active, not recruiting - Clinical trials for Mucopolysaccharidosis Type IIIB

A Treatment Extension Study of Mucopolysaccharidosis Type IIIB

Start date: February 19, 2018
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the long-term safety and tolerability of AX 250 administered to subjects with MPS IIIB by an implanted ICV reservoir and catheter and to evaluate the impact of long-term AX 250 treatment on cognitive function in patients with MPS IIIB as assessed by developmental quotient (DQ).

NCT ID: NCT03784170 Active, not recruiting - Clinical trials for Urinary Bladder, Overactive

FemPulse Therapy for Overactive Bladder in Women

EVANESCE-OAB
Start date: December 11, 2018
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.

NCT ID: NCT03783546 Active, not recruiting - Breast Cancer Clinical Trials

Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial

Start date: January 15, 2019
Phase: N/A
Study type: Interventional

This research study is evaluating acupuncture, a medical therapy in which hair-thin, stainless steel needles are shallowly inserted into specific points to help the body's natural healing process, as a possible treatment to reduce hot flashes.

NCT ID: NCT03783442 Active, not recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma (ESCC)

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Start date: December 11, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

NCT ID: NCT03783403 Active, not recruiting - Neoplasms Clinical Trials

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Start date: February 1, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.